Effectiveness of dolutegravir-based regimens as either first-line or switch antiretroviral therapy: data from the Icona cohort by Mondi, A. et al.
RESEARCH ARTICLE
Effectiveness of dolutegravir-based regimens as either first-line or
switch antiretroviral therapy: data from the Icona cohort
Annalisa Mondi1§ , Alessandro Cozzi-Lepri2, Alessandro Tavelli3, Stefano Rusconi4, Francesca Vichi5,
Francesca Ceccherini-Silberstein6, Andrea Calcagno7, Andrea De Luca8, Franco Maggiolo9, Giulia Marchetti10,
Andrea Antinori1, Antonella d’Arminio Monforte10 and on behalf of Icona Foundation Study Group*
§Corresponding author: Annalisa Mondi, HIV/AIDS Department, National Institute for Infectious DiseasesI “L. Spallanzani” IRCCS, Via Portuense 292, 00149 Rome,
Italy. Tel: +39-06.55170546. (annalisa.mondi@inmi.it)
*The members of Icona Foundation Study Group are listed in the Appendix.
Abstract
Introduction: Concerns about dolutegravir (DTG) tolerability in the real-life setting have recently arisen. We aimed to esti-
mate the risk of treatment discontinuation and virological failure of DTG-based regimens from a large cohort of HIV-infected
individuals.
Methods: We performed a multicentre, observational study including all antiretroviral therapy (ART)-na€ıve and virologically
suppressed treatment-experienced (TE) patients from the Icona (Italian Cohort Na€ıve Antiretrovirals) cohort who started, for
the first time, a DTG-based regimen from January 2015 to December 2017. We estimated the cumulative risk of DTG discon-
tinuation regardless of the reason and for toxicity, and of virological failure using Kaplan–Meier curves. We used Cox regres-
sion model to investigate predictors of DTG discontinuation.
Results: About 1679 individuals (932 ART-na€ıve, 747 TE) were included. The one- and two-year probabilities (95% CI) of
DTG discontinuation were 6.7% (4.9 to 8.4) and 11.5% (8.7 to 14.3) for ART-na€ıve and 6.6% (4.6 to 8.6) and 7.6% (5.4 to 9.8)
for TE subjects. In both ART-na€ıve and TE patients, discontinuations of DTG were mainly driven by toxicity with an estimated
risk (95% CI) of 4.0% (2.6 to 5.4) and 2.5% (1.3 to 3.6) by one year and 5.6% (3.8 to 7.5) and 4.0% (2.4 to 5.6) by two years
respectively. Neuropsychiatric events were the main reason for stopping DTG in both ART-na€ıve (2.1%) and TE (1.7%)
patients. In ART-na€ıve, a concomitant AIDS diagnosis predicted the risk of discontinuing DTG for any reason (adjusted relative
hazard (aRH) = 3.38, p = 0.001), whereas starting DTG in combination with abacavir (ABC) was associated with a higher risk
of discontinuing because of toxicity (aRH = 3.30, p = 0.009). TE patients starting a DTG-based dual therapy compared to a tri-
ple therapy had a lower risk of discontinuation for any reason (adjusted hazard ratio (aHR) = 2.50, p = 0.037 for ABC-based
triple-therapies, aHR = 3.56, p = 0.012 for tenofovir-based) and for toxicity (aHR = 5.26, p = 0.030 for ABC-based,
aHR = 6.60, p = 0.024 for tenofovir-based). The one- and two-year probabilities (95% CI) of virological failure were 1.2% (0.3
to 2.0) and 4.6% (2.7 to 6.5) in the ART na€ıve group and 2.2% (1.0 to 3.3) and 2.9% (1.5 to 4.3) in the TE group.
Conclusions: In this large cohort, DTG showed excellent efficacy and optimal tolerability both as first-line and switching ART.
The low risk of treatment-limiting toxicities in ART-na€ıve as well as in treated individuals reassures on the use of DTG in
everyday clinical practice.
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1 | INTRODUCTION
Despite its recent introduction, dolutegravir (DTG) is now one
of the most used antiretroviral drugs, thanks to its high effi-
cacy combined with convenient dosing, the lack of pharma-
cokinetic boosting requirement and the high barrier to
resistance. It is currently recommended both as first-line
therapy and as part of either switching strategies or salvage
regimens in pretreated patients in high-income countries [1].
Since July 2018, it is also recommended as a first-line treat-
ment option for resource-limited countries by World Health
Organization (WHO) treatment guidelines [2].
The efficacy of DTG in antiretroviral therapy (ART)-na€ıve
population has been widely demonstrated in randomized
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clinical trials, showing non-inferiority compared to raltegravir
[3], and superiority compared to both non-nucleoside reverse
transcriptase inhibitors [4] and protease inhibitors-based regi-
mens [5,6]. In these latter studies, the superiority of DTG was
mainly driven by a better tolerability of the drug compared to
its comparators, with a lower rate of treatment discontinua-
tions [4–6]. This elevated performance has been also con-
firmed in the treatment-experienced (TE) population both as
salvage therapy in heavily pretreated subjects [7,8], and sim-
plification strategy in virologically suppressed patients [9]. In
the latter context, DTG has also been investigated as part of
less drug regimens. While simplification to DTG monotherapy
has recently demonstrated suboptimal efficacy compared to
triple ART [10], recent randomized trials have demonstrated
the non-inferiority to standard ART of the two-drug regimens,
DTG plus rilpivirine in virologically suppressed subjects [11]
and DTG plus lamivudine (3TC) in ART-na€ıve patients [12].
This latter combination has also showed promising results as
a switching option in a non-randomized trial and in observa-
tional studies [13–15], whereas a large randomized clinical
trial exploring this strategy in now ongoing.
Despite the optimal safety profile demonstrated in clinical
trials [3–12], recent data from observational studies have
questioned the tolerability of DTG, reporting a high incidence
of discontinuations due to toxicity, mainly related to neuropsy-
chiatric events [16–18]. Although these findings were not uni-
formly confirmed [19–21], further studies are needed to
accurately estimate the tolerability profile of DTG-based regi-
mens in the real-life setting, even considered the forthcoming
broad use of DTG both as part of dual regimens in ART-na€ıve
and -experienced patients as well as first-line option in
resource-limited countries [2].
This study aimed to estimate the risk of DTG-discontinua-
tion and virological failure DTG-based regimens and to explore
the predictive factors of DTG interruptions in ART-na€ıve and
virologically suppressed TE patients, from a large cohort of
HIV-infected individuals.
2 | METHODS
2.1 | Study population
This is a retrospective analysis of prospectively collected data
from the Icona (Italan Cohort Na€ıve Antiretrovirals) Founda-
tion cohort. Icona is an observational cohort, set up in 1997,
including HIV-1-infected subjects, na€ıve from ART at the time
of enrolment, seen for care in Italy. To date, the cohort con-
sists of more than 16,000 patients prospectively followed in
51 centres. Demographic, viro-immunological and clinical data
together with information on antiretroviral regimens are col-
lected and recorded using an electronic database. Details of
the cohort have been described elsewhere [22].
Both ART-na€ıve and TE virologically suppressed patients
enrolled in the Icona cohort who initiated, for the first time,
any DTG-based regimen from January 2015 to December
2017, were included in the analysis. ART-experienced patients
were considered virologically suppressed if their most recent
available viral load before the DTG initiation was below
50 copies/mL. The reasons for DTG discontinuation, as
reported by the treating physicians, were recorded and classi-
fied into the following subgroups: simplification (defined as
either the reduction of drugs in the regimen or the decrease
in daily doses/pills), toxicity (defined as either side effects
potentially due to the prescribed drug or demonstrated toxic-
ity to the drug), failure (either virological, immunological or
clinical), adherence issues and unknown/other causes (e.g.
death, pregnancy, drug–drug interactions, enrolment in clinical
trials, physician’s choice not otherwise specified).
2.2 | Objectives
The primary objective was to estimate the risk of DTG discon-
tinuation regardless of the reason. Secondary objectives were
to assess the risk of DTG interruption due to toxicity and,
specifically, to neuropsychiatric adverse events and the risk of
virological failure. Moreover, factors independently associated
with the risk of DTG discontinuation for any reason and for
toxicity were identified. Only discontinuations of DTG were
considered, regardless of whether the remaining antiretroviral
drugs used in the combination had been stopped or not. Viro-
logical failure was defined at the time of the first of two con-
secutive HIV viral loads above the threshold of 50 copies/mL.
In ART-na€ıve patients, virological events were counted starting
from six months after ART initiation.
2.3 | Statistical analyses
Standard survival analysis by the Kaplan–Meier method was
used to estimate the cumulative probability of primary and
secondary endpoints as defined above with their respective
95% confidence intervals. We used a marginal model approach
to investigate the cumulative risk of DTG stop due to both
any and neuropsychiatric toxicity. In this model, the follow-up
of patients who discontinued for a reason different from gen-
eral or neuropsychiatric toxicity was truncated at the date of
last clinical follow-up. For the endpoints involving DTG discon-
tinuation participants’ follow-up accrued from the date of
DTG starting until its discontinuation or the last available clini-
cal visit. For the virological failure endpoint censoring was
applied at the date of participants’ last available viral load
measure. An intention-to-treat approach (ignoring treatment
change) was used for the virological failure analysis.
Multivariable Cox regression models were used to identify
factors independently associated with the risk of DTG discon-
tinuation for any reason and for toxicity. The following factors
were a priori included as covariates in the model: age, gender,
mode of HIV transmission, nationality, AIDS diagnosis, hepati-
tis coinfection, calendar year of starting DTG, most recent
CD4 count and HIV RNA (only for ART-na€ıve patients) at
DTG initiation, type of DTG-based regimen and, limited to TE
patients, previous virological failure, reasons for stopping pre-
vious regimen, duration of ART and of virological suppression
prior to DTG initiation. In the ART-na€ıve group, DTG-based
regimens were stratified according to the backbone. Con-
versely, in TE group, considering the more heterogeneous
types of regimens started, DTG-based therapies were strati-
fied according both to the backbone and to the type of regi-
men (abacavir (ABC)- vs. tenofovir-based standard triple
therapies vs. dual therapies). Since the two treatment groups
were heterogeneous for almost all the main baseline charac-
teristics, all analyses were performed separately for ART-na€ıve
and TE patients.
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All statistical analyses were performed using SAS (version
9.4, SAS Institute, Cary, NC, USA). All p-values presented are
two sided and a p-value < 0.05 indicated conventional statisti-
cal significance.
2.4 | Ethics statement
The Icona Foundation study was approved by the Ethics Com-
mittee (institutional review board) of each participating institu-
tion. All of the individuals enrolled provided a written
informed consent at the time of the enrolment. All procedures
of the study were performed in accordance with the 1964
Helsinki declaration and its later amendments.
3 | RESULTS
3.1 | Baseline patients’ characteristics
A total of 1679 HIV-positive patients, 932 ART-na€ıve and 747
TE, who started DTG for the first time in any antiretroviral
regimen, were included in the analysis. The main characteris-
tics of the study population at the time of DTG initiation,
overall and according to prior ART history, are shown in
Table 1. Briefly, of the 1679 subjects, 20% were female, the
median age was 44 years (interquartile range, IQR 35 to 52),
the majority of patients contracted HIV infection through sex-
ual intercourses (48% men having sex with men, 37% hetero-
sexual), only few individuals had a prior AIDS diagnosis (14%)
or were co-infected with hepatitis viruses (10%). DTG was
started in 1402 patients (84%) in a standard triple therapy
regimen (63% ABC-based; 37% tenofovir disoproxil fumarate
(TDF)/tenofovir alafenamide fumarate (TAF)-based), in 218
patients (13%) as part of a two-drug therapy and in 59 (4%)
patients in other regimens. As expected, the two populations
significantly differed for most of the baseline characteristics.
Particularly, ART-na€ıve patients were more likely to be
younger (p < 0.001), male (p = 0.002), non-Italian (p < 0.001)
and to have a higher CD4 cell count nadir (p < 0.001). Almost
all ART-na€ıve patients (95%) started a standard DTG-based
triple therapy (52% ABC-based, 48% tenofovir-based)
whereas, in the TE group, 70% of patients started DTG within
a standard triple ART, mainly ABC-based (81%) and 27%
started DTG as part of a dual therapy (p < 0.001 compared
to ART-na€ıve subjects).
3.2 | DTG discontinuation for any reason
Overall, over a median follow-up of 11 months (IQR 5 to 18),
121 subjects (7.2%) stopped DTG, of whom 71 were in the
ART-na€ıve group (7.6%) and 50 were in the TE group (6.7%).
Reasons for DTG discontinuations were similar across the two
groups. Specifically, toxicity was the most common cause for
treatment discontinuation in both ART-na€ıve and TE patients
(55% and 54% of DTG discontinuations) followed by lack of
efficacy (11% in ART-na€ıve vs. 6% in TE), simplification (8% vs.
10%) and adherence issues (4% vs. 6%) (Table 2).
In the ART-na€ıve group, the one- and two-year estimated
probability of discontinuing DTG regardless of the reason
were 6.7% (95% CI: 4.9 to 8.4) and 11.5% (95% CI: 8.7 to
14.3) respectively (Figure 1A). At multivariable Cox regression
analysis, after adjusting for potential confounders listed in the
Methods, patients diagnosed with an AIDS-defining event
were independently associated with a higher risk of stopping
DTG for any reason (adjusted hazard ratio, aHR = 3.38,
p = 0.001) (Table 3A). The AIDS-defining events which
occurred in 17 of 71 na€ıve patients who discontinued DTG
were: systemic Cytomegalovirus infection without end-organ
disease (n = 7), Pneumocystis jirovecii pneumonia (n = 5), eso-
phageal candidiasis (n = 4), tuberculosis (n = 3), Kaposi sar-
coma (n = 3), cerebral toxoplasmosis (n = 2), non-Hodgkin
lymphoma (n = 2), cervical cancer (n = 1) and AIDS dementia
complex (n = 1). More than one event for a patient could be
reported. Of note, five cases of immunoreconstituition inflam-
matory syndrome were reported in our ART-na€ıve population
(0.5% of all ART na€ıve patients, 4.6% of ART-na€ıve patients
with a concurrent AIDS diagnosis). Among them, just one
patient discontinued DTG.
In the ART-experienced population, the Kaplan–Meier esti-
mates of DTG interruption for any reason were 6.6% (95%
CI: 4.6 to 8.6) and 7.6% (95% CI: 5.4 to 9.8) by one and two
years respectively (Figure 1B). At multivariable analysis, TE
patients starting DTG as part of a dual regimen compared to
triple therapy, regardless of the backbone, had a lower risk of
discontinuation for any cause (aHR 2.50 for ABC-based triple
therapies, p = 0.037; aHR 3.56 for tenofovir-based triple ther-
apies, p = 0.012) (Table 3B). A more durable virological sup-
pression was also associated with a lower risk of interrupting
DTG regardless of the reason (aHR per six months longer:
0.94, p = 0.028).
It is worth mentioning that five pregnancies occurred in our
population over the observation time. All the five women were
on DTG at the time of the conception. Three of them discon-
tinued DTG within the first trimester of pregnancy, while two
continued the drug throughout the entire pregnancy. No new-
born safety issues have so far been reported.
3.3 | Toxicity-driven DTG discontinuation
Overall, DTG discontinuation was driven by toxicity in 66
patients (3.9% of total population, 55% of those who discon-
tinued). All the adverse events were mild or moderate and
none of them led to hospitalization or death. Neuropsychiatric
adverse events, although rarely observed (2.0%), were the
main cause of DTG discontinuation both for toxicity (33/66
(50%) of stops due to adverse events) and for any cause (33/
121 (27%) of total stops). In our population, the most com-
plained neuropsychiatric symptoms leading to DTG discontinu-
ation were insomnia (n = 11), depression (n = 5), anxiety/
mood disorders (n = 5) and headache (n = 5). Three patients
in the ART-na€ıve group reported suicidal ideation. A detailed
description of the neuropsychiatric symptoms leading to DTG
stop is shown in Table 2. A description of the toxicities lead-
ing to DTG discontinuation according to treatment group and
gender is reported in Table S1.
Among ART-na€ıve patients, 39 individuals (4.2%) stopped
DTG for an adverse event. Neuropsychiatric events and aller-
gic reactions were the most reported adverse events leading
to DTG discontinuations (2.1% and 1.0% respectively)
(Table 2). At survival analysis, the estimated one- and two-
year probabilities of discontinuing DTG because of adverse
events were 4.0% (95% CI: 2.6 to 5.4) and 5.6% (95% CI: 3.8
to 7.5) respectively (Figure 1C). Restricting the analysis to
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Table 1. Main baseline characteristics of total population and according to the treatment group
ART-naive Treatment-experienced
p-Value
Total
N = 932 N = 747 N = 1679
Gender, n (%) 0.002
Female 159 (17.1) 172 (23.0) 331 (19.7)
Age, years <0.001
Median (IQR) 40 (32 to 49) 48 (39 to 55) 44 (35 to 52)
Mode of HIV transmission, n (%) <0.001
MSM 487 (52.9) 313 (42.0) 800 (48.0)
Heterosexual 313 (33.6) 299 (40.0) 612 (36.5)
IDU 38 (4.1) 91 (12.2) 129 (7.7)
Other/unknown 83 (9.0) 42 (5.6) 125 (7.5)
Nationality, n (%) <0.001
Non-Italian 193 (20.7) 67 (9.0) 260 (15.5)
AIDS diagnosis, n (%) <0.001
Yes 108 (11.6) 129 (17.3) 237 (14.1)
HBsAg, n (%) <0.001
Negative 683 (73.3) 659 (88.2) 1342 (79.9)
Positive 1 (0.1) 12 (1.6) 13 (0.8)
Not tested 248 (26.6) 76 (10.2) 324 (19.3)
HCVAb, n (%) <0.001
Negative 655 (70.3) 581 (77.8) 1236 (73.6)
Positive 36 (3.9) 116 (15.5) 152 (9.1)
Not tested 241 (25.9) 50 (6.7) 291 (17.3)
Calendar year of baseline, n (%) <0.001
2015 217 (23.3) 225 (30.1) 442 (26.3)
2016 398 (42.7) 358 (47.9) 756 (45.0)
2017 317 (34.0) 164 (22.0) 481 (28.7)
CD4 count nadir, cells/mmc <0.001
Median (IQR) 345 (129 to 540) 272 (149 to 374) 301 (139 to 458)
Baseline CD4 count, cells/mmc <0.001
Median (IQR) 350 (127 to 562) 651 (463 to 862) 500 (276 to 726)
HIV RNA, log10 copies/mL
>100,000 copies/mL, n (%) 349 (42.3) – – 349 (22.2)
Type of DTG-based regimen started, n (%)
Standard triple therapy 882 (94.6) 520 (69.6) <0.001 1402 (83.5)
ABC-based 461 (52.3) 422 (81.2) 883 (63.0)
TDF-based 372 (42.2) 94 (18.1) 466 (33.2)
TAF-based 49 (5.6) 4 (0.8) 53 (3.8)
Dual therapy 14 (1.5) 204 (27.3) <0.001 218 (13.0)
DTG + RPV 2 (14.3) 34 (16.7) 36 (16.5)
DTG + 3TC 3 (21.4) 122 (59.8) 125 (57.3)
DTG + DRV/b 8 (57.1) 33 (16.2) 41 (18.8)
Other dual regimens 1 (7.1) 15 (7.4) 16 (7.3)
Other 36 (3.9) 23 (3.1) 0.386 59 (3.5)
DTG dosage (%) 0.024
QD 923 (99.0) 742 (99.3) 1665 (99.2)
BID 9 (1.0) 5 (0.7) 14 (0.8)
History of failure, n (%) –
Any failure – 259 (34.6) – 259 (15.4)
Failure to INSTI 17 (2.3) 17 (1.0)
Duration of VS ≤ 50 copies/mL, months –
Median (IQR) 43 (21 to 80)
Follow-up time, months <0.001
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neuropsychiatric toxicity, the estimated probabilities of inter-
rupting DTG because of a neuropsychiatric event were 2.1%
(95% CI: 1.0 to 3.1) by one year and 2.5% (95% CI: 1.3 to
3.8) by two years (Figure 1E). Having started DTG in combi-
nation with ABC compared to TDF or TAF was the only factor
associated with a significantly higher risk of interrupting DTG
for adverse events in previously untreated patients by
multivariable analysis (aHR = 3.30, p = 0.009) (Table 3A). It is
worth mentioning that none of the ART-na€ıve patients who
discontinued DTG for toxicity had changed the initial back-
bone before the event. In the TE group, 27 DTG discontinua-
tions (3.6% of TE patients) were motivated by adverse events,
mostly of a neuropsychiatric and gastrointestinal nature (1.7%
and 0.8% respectively) (Table 2). At survival analysis, the one-
year estimated probability of interrupting DTG because of
both any and neuropsychiatric adverse events in pretreated
patients were 2.5% (95% CI: 1.3 to 3.6) and 1.2% (95% CI:
0.4 to 2.0) respectively. The two-year estimated probabilities
of discontinuation were 4.0% (95% CI: 2.4 to 5.6) for any
adverse event and 1.7% (95% CI: 0.6 to 2.7) for neuropsychi-
atric toxicity (Figure 1D,F). At multivariable analysis, starting
DTG as a part of a dual regimen compared to a standard tri-
ple therapy confirmed its association with a lower probability
of interrupting DTG due to toxicity (aHR 5.26 for ABC-based
triple therapies, p = 0.030; aHR 6.60 for tenofovir-based tri-
ple therapies, p = 0.024) (Table 3B). The significantly lower
risk of DTG discontinuation for both any reason and for toxic-
ity with dual regimens over triple therapies was also con-
firmed after adjusting the results for patients’ comorbidities
(cardiovascular risk class, renal function, cholesterol levels)
(data not shown).
3.4 | Virological failure
Overall, during the observation time, virological failure
occurred in 45 patients (2.7%) of whom 24 were ART-na€ıve
(2.6%) and 21 were TE (2.8%) patients. The Kaplan–Meier
estimated probabilities of experiencing virological failure at
one and two years of treatment were 1.2% (95% CI: 0.3 to
2.0) and 4.6% (95% CI: 2.7 to 6.5) in the ART na€ıve group
and 2.2% (95% CI: 1.0 to 3.3) and 2.9% (95% CI: 1.5 to 4.3)
in the TE group respectively (Figure 1G,H). Particularly, in the
subgroup of 122 TE patients who switched to DTG plus 3TC
dual regimen, only one patient (0.8%) experienced virological
failure over the entire follow-up. The genotype resistance test
after virological failure, performed in 10 patients (four ART-
na€ıve and six TE), did not show the emergence of new major
drug resistance mutations.
4 | DISCUSSION
In this large observational study, including 1679 HIV-infected
individuals (of whom 932 ART-na€ıve) starting a DTG-based
Table 1. (Continued)
ART-naive Treatment-experienced
p-Value
Total
N = 932 N = 747 N = 1679
Median (IQR) 9 (3 to 17) 13 (6 to 20) 11 (5 to 18)
ART, antiretroviral therapy; IQR, interquartile range; MSM, men sex with men; IDU, intravenous drug user; Ag, antigen; Ab, antibodies; ABC, aba-
cavir; TDF, tenofovir disoproxil fumarate; TAF, tenofovir alafenamide fumarate; DTG, dolutegravir; RPV, rilpivrine; 3TC, lamivudine; DRV/b, daruna-
vir/ritonravir or darunavir/cobicistat; QD, quaque die; BID, bis in die; INSTI, integrase strand transfer inhibitor; VS, viral suppression. Bold values
in the third column represent statistically significant p-values. Bold values in the first and second columns represent the total number of patient
per class of antiretroviral regimen and are the sum of the number reported below in the column.
Table 2. Reasons for DTG discontinuation regardless of the
reason and due to toxicity according to treatment group
ART-na€ıve TE
Reasons for DTG discontinuation (n (% population))a
Toxicity 39 (4.2) 27 (3.6)
Lack of efficacy 8 (0.9) 3 (0.4)
Simplification 6 (0.6) 5 (0.6)
Adherence issues 3 (0.3) 3 (0.4)
Other/unknown 15 (1.6) 12 (1.6)
AEs Leading to DTG discontinuation (n (% population))a
Neuropsychiatric 20 (2.1) 13 (1.7)
Gastrointestinal 3 (0.3) 6 (0.8)
Allergic reactions 9 (1.0) –
Hepatic 3 (0.3) 1 (0.1)
Osteoarticular – 3 (0.4)
Renal 1 (0.1) 2 (0.3)
Other/unknown 3 (0.3) 2 (0.3)
Neuropsychiatric AEs leading to DTG discontinuation (n)b
Insomnia 7 4
Depression 4 1
Anxiety and mood disorders 4 1
Paraesthesia 2 1
Dizziness 1 2
Headache 2 3
Suicidal ideation 2 0
Other neurological AEsc 5 1
Other psychiatric AEsd 2 0
Not specified 1 0
ART, antiretroviral therapy; TE, treatment-experienced; DTG, dolute-
gravir; AEs, adverse events.
aFor each patient, only one main reason for DTG discontinuation and
one category of toxicity leading to DTG discontinuation is possible;
bmore than one neuropsychiatric symptoms for each patient is possi-
ble; cART-na€ıve: anosmia, photophobia, visual disturbances, cognitive-
motor slowing; TE: tinnitus; dART na€ıve patients: paranoid behaviour,
hallucinations.
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Figure 1. Kaplan–Meier curves estimating cumulative probability of dolutegravir (DTG)-discontinuation regardless of the reason (A,B), for
toxicity (C,D) and for neuropsychiatric adverse events (E,F) and the cumulative probability of virological failure (G,H) in antiretroviral therapy
(ART)-na€ıve and treatment-experienced (TE) groups.
Mondi A et al. Journal of the International AIDS Society 2019, 22:e25227
http://onlinelibrary.wiley.com/doi/10.1002/jia2.25227/full | https://doi.org/10.1002/jia2.25227
6
therapy for the first time showed optimal efficacy and high
tolerability with an overall low rates of virological failures
(2.7%) and treatment discontinuations (7.2%). Consistently
with data from postregistration studies [16–19,21] in our pop-
ulation, toxicity, mainly related to neuropsychiatric events, was
the leading reason for stopping DTG. Particularly, in line with
previous findings [17,23], insomnia along with depression and
mood disorders were the most frequently complained neu-
ropsychiatric symptoms leading to DTG stop.
Nonetheless, the rates of DTG discontinuation due to
adverse events and, specifically, to neuropsychiatric events
observed in this study (3.9% and 2.0%, respectively) were con-
siderably lower compared to several recent observational stud-
ies showing rates of DTG interruptions ranging from 7.6% to
13.7% [16–18], with the highest occurrence reported in the
Dutch cohort (13.7%, 71% due to neuropsychiatric toxicity)
[16]. In the large cohort examined by Hoffman et al., although
the rates of adverse events leading to treatment stop were sim-
ilar between DTG and elvitegravir (7.6% at 12 months), the risk
of discontinuing treatment for neuropsychiatric events was con-
sistently higher for the former (5.6% vs. 0.7% at 12 months)
[17]. However, this increased risk of DTG discontinuation due
Table 3. Predictors of DTG discontinuation for any reason and for toxicity by multivariable Cox regression models according to
treatment group (A: ART-na€ıve group and B: TE group)
(A) ART-na€ıve group
Variables
Discontinuation for any reason Discontinuation for toxicity
aRHa (95% CI) p-Value aRHa (95% CI) p-Value
Gender
Female 1.46 (0.67 to 3.19) 0.340 1.48 (0.45 to 4.84) 0.515
Age, years
Per 10 older 1.15 (0.94 to 1.40) 0.181 1.26 (0.88 to 1.79) 0.208
AIDS diagnosis
Yes vs. no 3.38 (1.62 to 7.05) 0.001 2.82 (0.96 to 8.28) 0.060
Calendar year of baseline
Per more recent year 1.26 (0.81 to 1.95) 0.313 1.37 (0.74 to 2.52) 0.318
Baseline CD4 count, cells/mmc
Per 100 higher 0.98 (0.86 to 1.11) 0.730 0.96 (0.81 to 1.13) 0.601
HIV-RNA, log10 copies/mL
Per log higher 1.27 (0.87 to 1.84) 0.216 1.13 (0.69 to 1.87) 0.623
NRTI backbone
TDF or TAF/FTC 1.00 1.00
3TC/ABC 1.39 (0.79 to 2.46) 0.253 3.30 (1.34 to 8.11) 0.009
(B) TE group
Variables
Discontinuation for any reason Discontinuation for toxicity
aRHb (95% CI) p-Value aRHb (95% CI) p-Value
Gender
Female 1.11 (0.52 to 2.33) 0.799 1.78 (0.66 to 4.78) 0.255
Age, years
Per 10 older 1.07 (0.81 to 1.41) 0.639 0.97 (0.66 to 1.42) 0.869
AIDS diagnosis
Yes vs. no 1.32 (0.64 to 2.72) 0.450 1.35 (0.50 to 3.68) 0.552
Calendar year of baseline
Per more recent year 1.06 (0.60 to 1.88) 0.839 0.89 (0.43 to 1.87) 0.767
DTG-regimenc
Dual 1.00 1.00
Triple with ABC 2.50 (1.06 to 5.93) 0.037 5.26 (1.17 to 23.56) 0.030
Triple with TDF/TAF 3.56 (1.33 to 9.53) 0.012 6.60 (1.29 to 33.85) 0.024
Duration of VS
Per six months longer 0.94 (0.88 to 0.99) 0.028 0.94 (0.83 to 1.07) 0.352
ART, antiretroviral therapy; TE, treatment-experienced; aRH, adjusted relative hazard; CI, confidence intervals; NRTI, nucleoside reverse transcrip-
tase inhibitor; FTC, emtricitabine; 3TC, lamivudine; DTG, dolutegravir; ABC, abacavir; TDF, tenofovir disoproxil fumarate; TAF, tenofovir alafe-
namide fumarate; VS, viral suppression. Bold values represent statistically significant p-values.
aAfter adjusting mode of HIV transmission, nationality, hepatitis coinfection; bafter adjusting for mode of HIV transmission, nationality, hepatitis co-
infection, baseline CD4 cell count, reasons for stopping previous regimen, previous virological failure, duration of ART; cother therapies group not
shown because no events occurred.
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to toxicity was not uniformly confirmed in real-life settings. In
fact, in line with our findings, several observational studies
reported lower rates of discontinuation of DTG-based regimens
because of toxicity [19–21], with a tolerability profile compara-
ble to the other integrase strand transfer inhibitors [19,21]. In
particular, the Swiss HIV cohort study, reported rates of DTG
discontinuation within the first year, due to both unspecified
and neuropsychiatric toxicity, comparable to our results (3.9%
and 1.7% respectively) [21]. Currently, to the best of our knowl-
edge, the rates of DTG discontinuation regardless of the reason
and related to toxicity in our study are among the lowest
reported in a real-life setting. Of note, our results are compara-
ble to those reported in randomized and non-randomized clini-
cal trials (1% to 12% discontinuations for any reason and 0% to
4% discontinuations due to adverse events after 12 months)
which are, however, likely to include selected populations at
lower risk of adverse events, therefore limiting the generaliz-
ability of the findings [3–12]. The heterogeneous composition of
study populations might partially explain the discrepant discon-
tinuation rates between our study and previous observational
reports. In particular, our results are based, as for the Swiss
cohort [21], on a nation-wide HIV cohort including patients
from multiple different centres and, thus, are probably less
influenced by patients’ selection or channelling biases than
specifically designed observational prospective or retrospective
databases.
Noteworthy, to date, our cohort includes one of the largest
ART-na€ıve population treated with DTG considering clinical
trials as well as postmarketing studies. The low risk of toxicity
limiting DTG treatment (5.6% by two years) and the negligible
rates of neuropsychiatric events leading to DTG discontinua-
tion (2.1%) observed in our ART-na€ıve population are in line
with preliminary pharmacovigilance data reported from a large
Brazilian ART-na€ıve cohort showing extremely low rates of
DTG-related adverse events (2.7%), mostly related to neu-
ropsychiatric and gastrointestinal toxicities [24]. Despite the
differences in healthcare setting and HIV epidemiology, our
data might add reassuring information in the light of the
forthcoming broad use of DTG-based first-line therapies in
middle- and low-income countries after the recent update of
WHO guidelines recommendations [2]. Although DTG rollout
in resource-limited countries is predicted to be not only effec-
tive but also cost-effective, particularly in view of the increas-
ing prevalence of pretreatment NNRTI resistance [25], several
questions on DTG safety remain to be addressed, particularly
in special sub-populations as severely immunocompromised
patients and pregnant women [26,27]. In this latter group,
surveillance data from Botswana cohort have recently
reported potential risk of neural tube defects in infants born
to women who were taking DTG at the time of conception
[28], leading to the release of a safety alert on DTG use in
pregnancy [29]. Although no birth defects were reported in
women exposed to DTG at the time of conception in our
cohort, the few pregnancies that occurred, the low number of
women of childbearing age and the deficiency on pregnancy
outcomes, do not allow this study to address any concerns on
DTG use during pregnancy.
Concerning predictive factors of DTG interruption, in our
ART-na€ıve population, a concurrent AIDS diagnosis predicted
a higher risk of discontinuing DTG regardless of the reason.
Toxicity issues, potential pharmacological interactions along
with compromised patients’ clinical condition could partially
explain this finding. Ongoing clinical trials with less restrictive
exclusion criteria will probably contribute to better clarify this
association, which assume a remarkable importance in the
light of the future extensive use of DTG in resource-limited
countries where HIV diagnosis and ART initiation generally
occurs at a more advanced stage of the disease.
Consistently with previous findings [16,17], in our cohort,
ART-na€ıve patients starting DTG in combination with ABC were
at higher risk of experiencing adverse events leading to treat-
ment discontinuation compared to TAF or TDF. Pharmacoki-
netic-driven drug–drug interaction, initially postulated to
explain this result [16], has been contradicted by further evi-
dence [30]. This finding, to date not confirmed in previously ran-
domized clinical trials in which DTG and ABC were co-
administrated [3,6], should be taken with caution because
potential bias due to selection or due to an enhanced awareness
of treating physicians on DTG tolerability cannot be ruled out.
In the TE group, patients starting a DTG-based dual therapy
showed a lower risk of drug interruption for any reason and
for toxicity as compared to the subjects on a triple therapy,
even after considering patients’ baseline comorbidities and
history of previous failure. However, channelling bias cannot
be completely ruled out. Indeed, heavily pretreated patients
with fewer therapeutic options left or more adherent patients
could be preferentially selected by physicians to start a less-
drug regimen than a triple therapy. Although GEMINI trials
did not show any differences in terms of discontinuations for
toxicity between DTG plus 3TC and DTG-based triple thera-
pies in ART-na€ıve patients [12], data from controlled clinical
trials comparing DTG-based dual and triple ART in TE patients
are awaited in order to verify this result. If the low risk of dis-
continuation of DTG-based dual versus triple regimens in pre-
treated patients is confirmed, the choice of DTG-based dual
regimens as switching strategy will become more attractive,
adding the advantage of the good tolerability to the already
demonstrated high potency, low potential for drug interactions
and low cost.
This study is not without limitations, including the observa-
tional nature of the study, which is prone to bias due to
unmeasured confounders, the short follow-up duration with a
median less than one year, the possible patient selection
biases, the incomplete information available about concomitant
medications and the potential inaccurate reporting of reasons
for DTG discontinuation. Nonetheless, this study has it
strengths in the description of the real-life setting and the
large sample size, especially for the ART-na€ıve patients.
5 | CONCLUSIONS
In conclusion, we provided further evidence that DTG has an
excellent virological efficacy in both ART-na€ıve and TE
patients. Furthermore, our data suggest a high tolerability of
DTG-based regimens as first-line therapy in ART-na€ıve
patients as well as switching strategy in TE virologically sup-
pressed patients, thus reassuring on the use of DTG in clinical
practice. Although adverse events, especially neuropsychiatric
symptoms, represented the main reason for stopping DTG,
their frequency was relatively low. Severely immunocompro-
mised ART-na€ıve patients appeared to be at higher risk of
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DTG discontinuation and, thus, warrant a closer monitoring.
While awaiting for the results of randomized trials comparing
dual versus triple DTG-based therapies in TE aviremic
patients, our data offer an insight into this question.
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